SialoTec GmbH develops innovative immunotherapies with a focus on immunity and cancer. The company’s mission is to transform its IP portfolio into clinical stage therapeutics. SialoTec’s first development programme is a game changing approach for B cell malignancies using a small molecule that enables selective delivery of therapy to disease B cells.

Investors and potential partners interested in small molecule based B lymphocyte specific delivery are welcome to contact us at: info@sialotec.de